AIM To study the efficacy and safety of PCSK9 inhibitor in lipid-lowering therapy in patients with ultra-high-risk atherosclerotic cardiovascular disease.
METHODS Continuously collected for this study were 138 ultra-high-risk ASCVD patients who received PCI treatment from September 2017 to March 2020 at the First Affiliated Hospital (Xijing Hospital) of the Air Force Military Medical University. After operation, all except one patient were treated with statins based lipid-lowering regimen combined with PCSK9 inhibitors and the one patient was treated with PCSK9 inhibitor alone due to statins allergy. Their blood lipid levels were detected after 1 to 3 months of medication and the lipid-lowering effect and adverse drug reactions were observed.
RESULTS A total of 138 patients were enrolled in this study. Among the 138 patients. Blood lipid levels before and after PCSK9 inhibitor treatment were TC、TG、LDL-C(P<0.005). The compliance rate of LDL-C<1.4 mmol/L and the average decrease of LDL-C were lower than before and the difference was statistically significant (P<0.01). No liver and kidney function damage, blood sugar level changes, or other adverse reactions were observed in all the patients.
CONCLUSION PCSK9 inhibitors effectively reduce the LDL-C level of patients with ultra-high-risk ASCVD and significantly increase their LDL-C compliance rate, with good effectiveness and safety.
DownLoad: